Drugs / Insulin Lispro Biphasic 25
last change Dec 2020 re-read 2 minutes ago

Insulin Lispro Biphasic 25

also known as GP40021
Developed for
type 2 diabetes mellitus
Investigated by
Geropharm

Trials 1 · a red edge is where a trial was stopped

201820192020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT04023344 Mar 2018 → Jan 2019 type 2 diabetes mellitus Geropharm Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as Insulin Lispro Biphasic 25 ClinicalTrials.gov intervention name — accepted as the source's own label NCT04023344
Known as GP40021 “Efficacy and safety of GP40021 insulin lispro biphasic compared with Humalog Mix 25 in Type 2 diabetes mellitus patients.” PMID 33355484 Dec 2020
Route Subcutaneous “Subcutaneus injections Insulin Lispro Biphasic 25” NCT04023344